Literature DB >> 6174218

Potentiation of the direct anticellular activity of mouse interferons: mutual synergism and interferon concentration dependence.

W R Fleischmann.   

Abstract

Mouse immune (IFN-gamma)2 and virus-type (IFN-alpha/beta) interferons were used separately and in combination in cloning studies with B-16 melanoma cells. IFN-gamma was found to be a more potent mediator of the direct anticellular effect of interferon than was IFN-alpha/beta, as shown not only by a greater sensitivity of B-16 cells to IFN-gamma but also by a steeper slope of the anticellular sensitivity curve of the IFN-gamma. The differences in the slopes of the curves defining their anticellular effect appeared to be inherent in the interferons themselves and not due to an inhibitor of interferon, a stimulator of cell growth, or another factor possessing anticellular activity. The results are consistent with the interpretation that IFN-gamma and IFN-alpha/beta exert their anticellular effects by different mechanisms. The anticellular activity of interferon against B-16 melanoma replication until development was potentiated by mixed preparations of IFN-gamma and IFN-alpha/beta. The potentiation appeared to be an expression of a property of the interferons themselves. Replication units resistant to the potentiated activity of the interferons were not detected. Potentiation levels were dependent on the concentrations of both IFN-gamma and IFN-alpha/beta and continued to increase dramatically as the interferon concentrations increased. Maximum potentiation observed was 214-fold at the highest interferon concentrations used. The data suggested that potentiation is a mutual, synergistic interaction of IFN-gamma and IFN-alpha/beta.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6174218

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Posttranscriptional regulation of beta interferon expression in erythroid Friend cells treated with gamma interferon.

Authors:  G Marziali; G Fiorucci; E M Coccia; Z Percario; J Raber; A Battistini; G B Rossi; E Affabris; G Romeo
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.

Authors:  K Sriskandan; P Garner; J Watkinson; K W Pettingale; D Brinkley; F M Calman; D E Tee
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Beta and gamma interferons act synergistically to produce an antiviral state in cells resistant to both interferons individually.

Authors:  J A Lewis; A Huq; B Shan
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

Review 4.  Regulation of cell proliferation and differentiation by interferons.

Authors:  M J Clemens; M A McNurlan
Journal:  Biochem J       Date:  1985-03-01       Impact factor: 3.857

Review 5.  Alpha interferon: a look to the future.

Authors:  E M Bonnem
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

6.  Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons.

Authors:  C W Czarniecki; C W Fennie; D B Powers; D A Estell
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

7.  Human interferon-gamma enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-alpha and interferon-beta.

Authors:  A Dolei; M R Capobianchi; F Ameglio
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

8.  Differential effects of gamma interferon on expression of HLA class II molecules controlled by the DR and DC loci.

Authors:  F Ameglio; M R Capobianchi; A Dolei; R Tosi
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

9.  Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.

Authors:  H O Klein; G Golbach; P Voigt; C Coerper; C Bernhardt
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  Effects of scheduling and ascites-associated macrophages on combined antiproliferative activity of alpha-2b interferon and gamma-interferon in a clonogenic assay.

Authors:  J Higashihara; T Saito; M E Berens; C E Welander
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.